Aitia is an AI-driven biotechnology company. According to available information, its positioning is to revolutionize drug discovery by uncovering hidden disease mechanisms to identify breakthrough therapies.
In terms of its technical approach, the information mentions that it combines causal AI with human multi-omics data and uses a platform called Gemini Digital Twins, with the aim of accelerating the R&D process in the life sciences field.
Regarding the company's specific product features, how the platform operates, usage steps, applicable scenarios, pricing models, and capability boundaries, the available information does not currently provide these, so they cannot be further elaborated.